Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
AssigneePrecision BioSciences, Inc.
InventorsDerek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
Claims9
A pharmaceutical composition comprising a genetically-modified human T cell and a pharmaceutically acceptable carrier, wherein said genetically-modified human T cell comprises in its genome a modified human T cell receptor (TCR) alpha constant region gene, wherein said modified human TCR alpha constant region gene comprises from 5′ to 3′:
- (a) a 5′ region of a human TCR alpha constant region gene which is endogenous to said T cell;
- (b) an exogenous nucleic acid sequence encoding a chimeric antigen receptor;
- and
- (c) a 3′ region of said human TCR alpha constant region gene which is endogenous to said T cell;
- wherein said chimeric antigen receptor comprises a ligand-binding domain having specificity for an antigen present on a cancer cell, and wherein said genetically-modified human T cell expresses said chimeric antigen receptor and exhibits reduced cell-surface expression of the endogenous T cell receptor when compared to unmodified control cells.
Dependencies are inferred from the claim text.